Who Paid My Doc
Yutiq
Drug Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye
NDC 68611-180-01
General payments
$861,907
Research payments
$463,222
Through program year 2025, $861,907 in general payments and $463,222 in research payments were reported against Yutiq (Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
4 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | General | $82,010 | 1,371 |
| 2025 | Research | $161,074 | 75 |
| 2024 | General | $779,896 | 3,877 |
| 2024 | Research | $302,148 | 44 |
Breakdown
The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.
The top 5 of 18 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.
The top 5 of 42 states; each share is of general payments naming this product in 2025 where a state was reported.
Records
5,248 general · 119 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.